妊娠期乳腺癌（PrBC）的管理是一个相对罕见的适应症，目前并没有或只有很少的证据可供参考，因为无法进行随机对照试验。总的来说，关于妊娠期乳腺癌外的治疗进展并不能直接适用于PrBC，因为需要考虑到母亲和未出生婴儿的利益。在一些特定领域的证据仍然有限且存在冲突，最佳治疗方案仍然有争议。2022年，欧洲医学肿瘤学会（ESMO）在这个主题上举行了一个虚拟共识建立过程，以获得来自多学科专家组的见解，并就目前证据为基础的ESMO临床实践指南无法适当解决的有争议问题提出声明。这一共识建立过程的目标是讨论乳腺癌妊娠患者管理中的有争议问题。虚拟会议包括来自13个国家的24位领先专家组成的多学科小组，由S. Loibl和F. Amant担任主席。所有专家被分配到四个不同的工作小组中。每个工作小组涵盖一个特定的主题领域，并委任两个主席：1. 妊娠期乳腺癌：发生率、流行病学、生物学和病理学。诊断工作、分期和风险评估、预后（主席：Vincent Vandecaveye，Fedro Peccatori）2. 妊娠期系统药物的临床药理学。局限性疾病和（新）辅助治疗的管理。系统性疾病的治疗（主席：Giuseppe Curigliano，Peter Schmid）3. 产科护理和胎儿/新生儿随访和结果，胎儿转移。抗癌治疗期间的妊娠管理。哺乳。心理支持（主席：Elyce Cardonick，Mathilde van Gerwen）共识过程的规划、准备和执行按照ESMO标准操作规程进行。版权所有 © 2023，Elsevier Ltd.发布。

The management of breast cancer during pregnancy (PrBC) is a relatively rare indication and an area where no or little evidence is available since randomized controlled trials cannot be conducted. In general, advances related to breast cancer treatment outside pregnancy cannot always be translated to PrBC, because both the interests of the mother and of the unborn should be considered. Evidence remains limited and/or conflicting in some specific areas where the optimal approach remains controversial. In 2022, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process on this topic to gain insights from a multidisciplinary group of experts and develop statements on controversial topics that cannot be adequately addressed in the current evidence-based ESMO Clinical Practice Guideline. The aim of this consensus-building process was to discuss controversial issues relating to the management of patients with breast cancer during pregnancy. The virtual meeting included a multidisciplinary panel of 24 leading experts from 13 countries and was chaired by S. Loibl and F. Amant. All experts were allocated to one of four different working groups. Each working group covered a specific subject area with two chairs appointed: 1. Breast cancer during pregnancy: incidence, epidemiology, biology and pathology. Diagnostic work up, Staging and Risk assessment, prognosis (Chairs: Vincent Vandecaveye, Fedro Peccatori) 2. Clinical pharmacology of systemic agents during pregnancy. Management of localized disease and (neo) adjuvant therapies. Management of systemic disease (Chairs: Giuseppe Curigliano, Peter Schmid) 3. Obstetric care and fetal/newborn follow-up and outcomes, metastases to fetus. Management of pregnancy during anticancer therapy. Lactation. Psychological support (Chairs: Elyce Cardonick, Mathilde van Gerwen) Planning, preparation and execution of the consensus process was conducted according to the ESMO standard operating procedures.Copyright © 2023. Published by Elsevier Ltd.